Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study
Autor: | Oscar Luis Alves, Ronald L. Hayes, M. Ross Bullock, K. Niki Kunene, Charlotte Gilman, Christos M. Tolias, Anna Teresa Mazzeo |
---|---|
Rok vydání: | 2008 |
Předmět: |
Adult
Male Mean arterial pressure Microdialysis Traumatic brain injury Hemodynamics Neuroprotection Placebos Young Adult Double-Blind Method Cyclosporin a Pyruvic Acid Humans Medicine Cerebral perfusion pressure business.industry Head injury Brain Extracellular Fluid Middle Aged medicine.disease Mitochondria Glucose Neuroprotective Agents Treatment Outcome Brain Injuries Cerebrovascular Circulation Anesthesia Cyclosporine Female Surgery Neurology (clinical) Energy Metabolism business |
Zdroj: | Acta Neurochirurgica. 150:1019-1031 |
ISSN: | 0942-0940 0001-6268 |
DOI: | 10.1007/s00701-008-0021-7 |
Popis: | Mitochondrial dysfunction is a major limiting factor in neuronal recovery following traumatic brain injury. Cyclosporin A (CsA) has been recently proposed for use in the early phase after severe head injury, for its ability to preserve mitochondrial bioenergetic state, potentially exerting a neuroprotective effect. The aim of this study was, therefore, to evaluate the effect of CsA on brain energy metabolism, as measured by cerebral microdialysis, and on cerebral hemodynamics, in a group of severely head injured patients. Fifty adult patients with a severe head injury were enrolled in this randomized, double-blind, placebo-controlled study. Patients received 5 mg/kg of CsA over 24 h, or placebo, within 12 h of the injury. A microdialysis probe was placed in all patients, who were managed according to standard protocols for the treatment of severe head injury. The most robust result of this study was that, over most of the monitoring period, brain dialysate glucose was significantly higher in the CsA treated patients than in placebo. Both lactate and pyruvate were also significantly higher in the CsA group. Glutamate concentration and lactate/pyruvate ratio were significantly higher in the placebo group than in CsA treated patients, respectively 1 to 2 days, and 2 to 3 days after the end of the 24-h drug infusion. The administration of CsA was also associated with a significant increase in mean arterial pressure (MAP) and cerebral perfusion pressure (CPP). The administration of CsA in the early phase after head injury resulted in significantly higher extracellular fluid glucose and pyruvate, which may be evidence of a beneficial effect. The early administration of CsA was also associated with a significant increase in MAP and CPP and such a potentially beneficial hemodynamic effect might contribute to a neuroprotective effect. |
Databáze: | OpenAIRE |
Externí odkaz: |